ResMed Chief Product Officer Awarded 6,461 Performance RSUs

Executive Summary

On October 1, 2026, ResMed Inc. filed a Form 4 on behalf of Justin Leong, Chief Product Officer. The filing details the acquisition of 6,461 shares of ResMed Common Stock on August 14, 2026, stemming from the certification and earning of performance-based restricted stock units (RSUs).

Transaction Details

• Reporting Owner: Justin Leong, Chief Product Officer
• Security: ResMed Common Stock
• Transaction Code: A (Grant, award, or other acquisition)
• Shares Acquired: 6,461 shares
• Price Per Share: $0.00
• Total Consideration: $0.00
• Ownership After Transaction: 35,489 shares held directly

Additional Context & Footnotes

According to the explanatory footnote, the 6,461 shares represent performance-based RSUs initially granted on November 20, 2025. These RSUs were earned on August 14, 2026, following the Compensation and Leadership Development Committee's certification that applicable performance metrics had been satisfied. The earned RSUs vest one-third each year on the anniversary of the original grant date.

Market Impact & Significance

This transaction reflects routine executive equity compensation rather than discretionary open-market buying or selling. Consequently, it carries low trading significance for general market sentiment.